id: NEW:chronic_liver_disease_concurrent_to_NEW:hepatocellular_carcinoma_incidence
name: Concurrent Chronic Liver Disease (HBV, HCV, Alcohol) â†’ Hepatocellular Carcinoma
  Incidence
from_node:
  node_id: NEW:chronic_liver_disease_concurrent
  node_name: Concurrent Chronic Liver Disease (HBV, HCV, Alcohol)
to_node:
  node_id: NEW:hepatocellular_carcinoma_incidence
  node_name: Hepatocellular Carcinoma Incidence
direction: positive
category: biological
mechanism_pathway:
- 'Step 1: Chronic liver diseases (HBV, HCV, alcohol-related liver disease) cause
  persistent hepatic inflammation and hepatocyte injury'
- 'Step 2: When metabolic dysfunction-associated fatty liver disease (MAFLD) coexists
  with these conditions (mixed-MAFLD), additive or synergistic liver damage occurs
  through combined inflammatory, metabolic, and viral/toxic pathways'
- 'Step 3: The combined insults accelerate fibrogenesis and progression to cirrhosis,
  with mixed-MAFLD HCC showing significantly higher likelihood of cirrhosis compared
  to single-etiology MAFLD'
- 'Step 4: Cirrhotic liver provides the permissive environment for hepatocarcinogenesis
  through altered cell proliferation, oxidative stress, and impaired tumor surveillance'
- 'Step 5: The synergistic hepatotoxic effects result in high HCC incidence, with
  MAFLD prevalence reaching 40% in HBV-related, 54% in HCV-related, and 64% in alcohol-related
  HCC cases'
evidence:
  quality_rating: A
  n_studies: 22
  primary_citation: 'Harry Crane et al. 2024. Global prevalence of metabolic dysfunction-associated
    fatty liver disease-related hepatocellular carcinoma: A systematic review and
    meta-analysis. Clinical and Molecular Hepatology.'
  supporting_citations: []
description: Concurrent chronic liver diseases (HBV, HCV, alcohol-related liver disease)
  substantially increase hepatocellular carcinoma incidence, particularly when combined
  with metabolic dysfunction-associated fatty liver disease. This systematic review
  of 22 studies (56,565 HCC patients) found that nearly half of all HCC cases had
  MAFLD as a contributing factor, with mixed-etiology cases being more common than
  single-etiology MAFLD-HCC. The synergistic effect of concurrent liver diseases accelerates
  progression to cirrhosis and subsequent hepatocarcinogenesis.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
quantitative_effects:
  effect_size:
    value: 48.7
    type: prevalence_percentage
    ci_lower: 34.5
    ci_upper: 63.0
  p_value: null
  sample_size: 56565
moderators:
- name: Type of concurrent liver disease
  direction: strengthens
  strength: strong
  description: 'Mixed-MAFLD prevalence varies by etiology: alcohol-related (64.3%)
    > HCV (54.1%) > HBV (40.0%), suggesting alcohol has strongest synergistic effect
    with metabolic dysfunction'
- name: Cirrhosis status
  direction: strengthens
  strength: strong
  description: Mixed-MAFLD HCC had significantly higher likelihood of cirrhosis compared
    to single-MAFLD HCC, indicating cirrhosis mediates the pathway to HCC
